This technology is a mouse model and murine lymphoma line that allows for the conditional knock-in of the Vav1-Myof1 fusion oncogene in CD4+ T cells.
Unmet Need: In vitro and in vivo models for Peripheral T-cell Lymphoma
Peripheral T-cell Lymphomas (PTCLs) represent a heterogeneous and poorly understood pathological group of non-Hodgkin lymphomas associated with poor prognosis, particularly in those with the GATA3+ subtype. Mutations in the Vav1-Myof1 fusion oncogene can result in PTCL. Animal models are necessary to better understand the role of Vav1-Myof1 and develop targeted treatments for these disorders. However, there are currently few animal models to study PTCL in vivo, and none that look specifically at this oncogene.
The Technology: Conditional knock-in cell and mouse models for Peripheral T-cell Lymphoma
This technology is a mouse model and murine lymphoma line that allows for the conditional knock-in of the Vav1-Myof1 fusion oncogene in CD4+ T cells. It can be used to study PTCL with GATA3+ features and screen targeted treatments. It can also be used to understand the role of Vav1-Myof1 in hematological malignancies and screen potential therapeutics.
Applications:
- Therapeutic screening for PTCL
- Research tool for analysis of tumor microenvironment
- Research tool for analysis of tumor-suppressing agents
- Research tool for analysis of Peripheral T-cell lymphoma pathogenesis
- Diagnostic assays for cancers
- Genetic screening of cancerous mutations
Advantages:
- Replicates human diseases associated with Vav1-Myof1
- Creates consistent and reproducible genetic knockouts
- Knocks out Vav1-Myof1 only in specific cells of interest
- Provides a model of Peripheral T-cell Lymphoma with GATA3+ features
- High-throughput platform for disease analysis and drug screening
Lead Inventor:
Teresa Palomero, Ph.D.
Related Publications:
- Cortes JR, Filip I, Albero R, Patiño-Galindo JA, Quinn SA, Lin WW, Laurent AP, Shih BB, Brown JA, Cooke AJ, Mackey A, Einson J, Zairis S, Rivas-Delgado A, Laginestra MA, Pileri S, Campo E, Bhagat G, Ferrando AA, Rabadan R, Palomero T. “Oncogenic Vav1-Myo1f induces therapeutically targetable macrophage-rich tumor microenvironment in peripheral T cell lymphoma” Cell Rep. 2022 Apr; 39(3):110695
Tech Ventures Reference:
